Targeting mTOR signaling for cancer therapy

Current Opinion in Pharmacology

Volumn 3, Issue 4, 2003, Pages 371-377

  Huang, Shile ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; BINDING PROTEIN; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; FUNGICIDE; IMMUNOSUPPRESSIVE AGENT; INITIATION FACTOR 4E; LACTONE DERIVATIVE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIBOSOME PROTEIN; TEMSIROLIMUS; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOACCUMULATION; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER THERAPY; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; HYPERLIPIDEMIA; LUNG SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STOMATITIS; TRANSLATION INITIATION; TREATMENT PLANNING; TUMOR CELL LINE; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 0041802820     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00071-7     Document Type: Review

References (55)

1. Vogt P.K. PI 3-kinase, mTOR, protein synthesis and cancer Trends Mol Med 7 2001 482-484
2. Valentinis B. Baserga R.IGF-I receptor signalling in transformation and differentiation Mol Pathol 54 2001 133-137
3. Oldham S. Hafen E. Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control Trends Cell Biol 13 2003 79-85
4. Jacinto E. Hall M.N. Tor signalling in bugs, brain and brawn Nat Rev Mol Cell Biol 4 2003 117-126
5. Dancey J.E. Clinical development of mammalian target of rapamycin inhibitors Hematol Oncol Clin North Am 16 2002 1101-1114 The author summarizes recent data about CCI-779 from phase I clinical trials.
6. Huang S. Houghton P.J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic Curr Opin Investig Drugs 3 2002 295-304
7. DeFatta R.J. Li Y. De Benedetti A. Selective killing of cancer cells based on translational control of a suicide gene Cancer Gene Ther 9 2002 573-578
8. Kwon H.K. Bae G.U. Yoon J.W. Kim Y.K. Lee H.Y. Lee H.W. Han J.W. Constitutive activation of p70S6k in cancer cells Arch Pharm Res 25 2002 685-690
9. Kenerson H.L. Aicher L.D. True L.D. Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors Cancer Res 62 2002 5645-5650
10. Brown E.J. Albers M.W. Shin T.B. Ichikawa K. Keith C.T. Lane W.S. Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex Nature 369 1994 756-758
11. Gingras A.C. Raught B. Sonenberg N. Regulation of translation initiation by FRAP/mTOR Genes Dev 15 2001 807-826
12. Kunz J. Henriquez R. Schneider U. Deuter-Reinhard M. Movva N.R. Hall M.N. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression Cell 73 1993 585-596
13. Abraham R.T. Identification of TOR signaling complexes: more TORC for the cell growth engine Cell 111 2002 9-12
14. Fang Y. Vilella-Bach M. Bachmann R. Flanigan A. Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling Science 294 2001 1942-1945
15. Dennis P.B. Jaeschke A. Saitoh M. Fowler B. Kozma S.C. Thomas G. Mammalian TOR: a homeostatic ATP sensor Science 294 2001 1102-1105
16. Proud C.G. Regulation of mammalian translation factors by nutrients Eur J Biochem 269 2002 5338-5349
17. Peng T. Golub T.R. Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation Mol Cell Biol 22 2002 5575-5584
18. Braun-Dullaeus R.C. Mann M.J. Seay U. Zhang L. von Der Leyen H.E. Morris R.E. Dzau V.J. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin Arterioscler Thromb Vasc Biol 21 2001 1152-1158
19. Thomas G. The S6 kinase signaling pathway in the control of development and growth Biol Res 35 2002 305-313
20. Hudson C.C. Liu M. Chiang G.G. Otterness D.M. Loomis D.C. Kaper F. Giaccia A.J. Abraham R.T. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin Mol Cell Biol 22 2002 7004-7014
21. Treins C. Giorgetti-Peraldi S. Murdaca J. Semenza G.L. Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway J Biol Chem 277 2002 27975-27981
22. Guba M. von Breitenbuch P. Steinbauer M. Koehl G. Flegel S. Hornung M. Bruns C.J. Zuelke C. Farkas S. Anthuber M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128-135 The authors show that rapamycin can inhibit tumour growth in vivo more potently because of its anti-angiogenesis effects.
23. Choi J.H. Bertram P.G. Drenan R. Carvalho J. Zhou H.H. Zheng X.F. The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase EMBO Rep 3 2002 988-994
24. Kim D.H. Sarbassov D.D. Ali S.M. King J.E. Latek R.R. Erdjument-Bromage H. Tempst P.Sabatini D.M.mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2002 163-175
25. Hara K. Maruki Y. Long X. Yoshino K. Oshiro N. Hidayat S. Tokunaga C. Avruch J. Yonezawa K.Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 110 2002 177-189.
26. Loewith R. Jacinto E. Wullschleger S. Lorberg A. Crespo J.L. Bonenfant D. Oppliger W. Jenoe P. Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol Cell 10 2002 457-468
27. Inoki K. Li Y. Zhu T. Wu J. Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling Nat Cell Biol 4 2002 648-657.
28. Gao X. Zhang Y. Arrazola P. Hino O. Kobayashi T. Yeung R.S. Ru B. Pan D. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling Nat Cell Biol 4 2002 699-704
29. Tee A.R. Fingar D.C. Manning B.D. Kwiatkowski D.J. Cantley L.C. Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling Proc Natl Acad Sci USA 99 2002 13571-13576
30. Potter C.J. Pedraza L.G. Xu T. Akt regulates growth by directly phosphorylating Tsc2 Nat Cell Biol 4 2002 658-665
31. Manning B.D. Tee A.R. Logsdon M.N. Blenis J. Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway Mol Cell 10 2002 151-162
32. Radimerski T. Montagne J. Hemmings-Mieszczak M. Thomas G. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling Genes Dev 16 2002 2627-2632
33. Jaeschke A. Hartkamp J. Saitoh M. Roworth W. Nobukuni T. Hodges A. Sampson J. Thomas G. Lamb R. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent J Cell Biol 159 2002 217-224
34. Erbay E. Chen J. The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism J Biol Chem 276 2001 36079-36082
35. Shu L. Zhang X. Houghton P.J. Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin J Biol Chem 277 2002 16726-16732
36. Kip1 in vascular smooth muscle cell migration Circulation 103 2001 2967-2972
37. Marx S.O. Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis Circulation 104 2001 852-855
38. Dudkin L. Dilling M.B. Cheshire P.J. Harwood F.C. Hollingshead M. Arbuck S.G. Travis R. Sausville E.A. Houghton P.J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clin Cancer Res 7 2001 1758-1764
39. Yu K. Toral-Barza L. Discafani C. Zhang W.G. Skotnicki J. Frost P. Gibbons J.J. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 2001 249-258
40. Neshat M.S. Mellinghoff I.K. Tran C. Stiles B. Thomas G. Petersen R. Frost P. Gibbons J.J. Wu H. Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 2001 10314-10319
41. +/- mice Proc Natl Acad Sci USA 98 2001 10320-10325.
42. Shi Y. Gera J. Hu L. Hsu J.H. Bookstein R. Li W. Lichtenstein A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res 62 2002 5027-5034
43. Huang S. Houghton P.J. Resistance to rapamycin: a novel anticancer drug Cancer Metastasis Rev 20 2001 69-78
44. CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin Cancer Res 61 2001 3373-3381 A paper showing that, under serum-free conditions, the response of tumour cells lacking functional p53 to rapamycin is apoptosis, whereas the response of normal cells is cytostasis.
45. Lieberthal W. Fuhro R. Andry C.C. Rennke H. Abernathy V.E. Koh J.S. Valeri R. Levine J.S. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells Am J Physiol Renal Physiol 281 2001 F693-F706
46. Thimmaiah K.N. Easton J. Huang S. Veverka K.A. Germain G.S. Harwood F.C. Houghton P.J. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathways Cancer Res 63 2003 364-374
47. KIP1 expression Blood 101 2003 1439-1445
48. Law B.K. Chytil A. Dumont N. Hamilton E.G. Waltner-Law M.E. Aakre M.E. Covington C. Moses H.L. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells Mol Cell Biol 22 2002 8184-8198
49. Harada H. Andersen J.S. Mann M. Terada N. Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD Proc Natl Acad Sci USA 98 2001 9666 9670
50. Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H, Houghton PJ: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21Cip1. Mol Cell 2003, in press.
51. Huang S. Houghton P.J. Mechanisms of resistance to rapamycins Drug Resist Updat 4 2001 378-391
52. Dilling M.B. Germain G.S. Dudkin L. Jayaraman A.L. Zhang X. Harwood F.C. Houghton P.J. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin J Biol Chem 277 2002 13907-13917
53. Geoerger B. Kerr K. Tang C.B. Fung K.M. Powell B. Sutton L.N. Phillips P.C. Janss A.J. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy Cancer Res 61 2001 1527-1532
54. Grunwald V. DeGraffenried L. Russel D. Friedrichs W.E. Ray R.B. Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells Cancer Res 62 2002 6141-6145
55. Eshleman J.S. Carlson B.L. Mladek A.C. Kastner B.D. Shide K.L. Sarkaria J.N. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy Cancer Res 62 2002 7291-7297